Trial Profile
A Phase II Study of PNT2258 in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status:
Suspended
Phase of Trial:
Phase II
Latest Information Update: 13 Jun 2023
Price :
$35
*
At a glance
- Drugs Rosomidnar (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- Acronyms Wolverine
- Sponsors Sierra Oncology
- 24 Feb 2017 Planned End Date changed from 1 Jan 2017 to 1 Jul 2018.
- 24 Feb 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Jul 2018.
- 09 Jan 2017 According to a Sierra Oncology media release, this trial was originally conducted by ProNAi Therapeutics, Inc. but later on this company's name changed to Sierra Oncology.